Tags

Type your tag names separated by a space and hit enter

The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients.

Abstract

The effect of selenium (Se) in reducing the toxicity of cisplatin in cancer patients was studied. Forty-one patients were randomized into group A (20 patients with Se administration in first cycle of chemotherapy as study cases and without Se in second cycle of chemotherapy as control) and group B (21 patients without Se in first cycle of chemotherapy and with Se in second cycle of chemotherapy). The 4000 micrograms per day of Se as Seleno-Kappacarrageenan were administered from 4 before to 4 d after chemotherapy for study cases. The serum Se increased from 70.4 +/- 22.86 to 157.04 +/- 60.23 ng/mL (P < 0.001) in patients received Se. The cisplatin dosage was iv administration in 60-80 mg/m2 on the first day. The results showed that the peripheral WBC counts on day 14 after initiation of chemotherapy in study cases was significantly higher than the controls (3.35 +/- 2.01 vs 2.31 +/- 1.38 [x10(9)L])/L, p < 0.05). On the other hand, the consumption of GCSF for the cases was significantly less than the controls (110.1 +/- 82.2 vs 723.6 +/- 192.6 IU, p < 0.05). The volumes of blood transfusion for the study group were also significantly less than the controls (0 vs 62 +/- 38 mL, p < 0.05). The nephrotoxicity of cisplatin was measured by urine enzymes (NAG, GGT, AAP, LAP, and ALP) were determined prior to and at 2, 24, 48, and 72 h after initiation of chemotherapy. The urine enzymes NAG, GGT, AAP, and ALP after chemotherapy for cases were significantly lower than the controls. No toxicity of Seleno-Kappacarrageenan was noted. The above results suggest that the Se can be used as an agent for reducing the nephrotoxicity and bone marrow suppression induced by cisplatin.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Medical Oncology, Beijing Hospital, P.R., China.

    , , , , , , , , ,

    Source

    Biological trace element research 56:3 1997 Mar pg 331-41

    MeSH

    Administration, Oral
    Adult
    Aged
    Antineoplastic Combined Chemotherapy Protocols
    Bone Marrow
    Carrageenan
    Cisplatin
    Cross-Over Studies
    Drug Synergism
    Female
    Humans
    Injections, Intravenous
    Kidney
    Male
    Middle Aged
    Random Allocation
    Selenium

    Pub Type(s)

    Clinical Trial
    Comparative Study
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    9197929

    Citation

    Hu, Y J., et al. "The Protective Role of Selenium On the Toxicity of Cisplatin-contained Chemotherapy Regimen in Cancer Patients." Biological Trace Element Research, vol. 56, no. 3, 1997, pp. 331-41.
    Hu YJ, Chen Y, Zhang YQ, et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res. 1997;56(3):331-41.
    Hu, Y. J., Chen, Y., Zhang, Y. Q., Zhou, M. Z., Song, X. M., Zhang, B. Z., ... Cheng, G. (1997). The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biological Trace Element Research, 56(3), pp. 331-41.
    Hu YJ, et al. The Protective Role of Selenium On the Toxicity of Cisplatin-contained Chemotherapy Regimen in Cancer Patients. Biol Trace Elem Res. 1997;56(3):331-41. PubMed PMID: 9197929.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. AU - Hu,Y J, AU - Chen,Y, AU - Zhang,Y Q, AU - Zhou,M Z, AU - Song,X M, AU - Zhang,B Z, AU - Luo,L, AU - Xu,P M, AU - Zhao,Y N, AU - Zhao,Y B, AU - Cheng,G, PY - 1997/3/1/pubmed PY - 1997/3/1/medline PY - 1997/3/1/entrez SP - 331 EP - 41 JF - Biological trace element research JO - Biol Trace Elem Res VL - 56 IS - 3 N2 - The effect of selenium (Se) in reducing the toxicity of cisplatin in cancer patients was studied. Forty-one patients were randomized into group A (20 patients with Se administration in first cycle of chemotherapy as study cases and without Se in second cycle of chemotherapy as control) and group B (21 patients without Se in first cycle of chemotherapy and with Se in second cycle of chemotherapy). The 4000 micrograms per day of Se as Seleno-Kappacarrageenan were administered from 4 before to 4 d after chemotherapy for study cases. The serum Se increased from 70.4 +/- 22.86 to 157.04 +/- 60.23 ng/mL (P < 0.001) in patients received Se. The cisplatin dosage was iv administration in 60-80 mg/m2 on the first day. The results showed that the peripheral WBC counts on day 14 after initiation of chemotherapy in study cases was significantly higher than the controls (3.35 +/- 2.01 vs 2.31 +/- 1.38 [x10(9)L])/L, p < 0.05). On the other hand, the consumption of GCSF for the cases was significantly less than the controls (110.1 +/- 82.2 vs 723.6 +/- 192.6 IU, p < 0.05). The volumes of blood transfusion for the study group were also significantly less than the controls (0 vs 62 +/- 38 mL, p < 0.05). The nephrotoxicity of cisplatin was measured by urine enzymes (NAG, GGT, AAP, LAP, and ALP) were determined prior to and at 2, 24, 48, and 72 h after initiation of chemotherapy. The urine enzymes NAG, GGT, AAP, and ALP after chemotherapy for cases were significantly lower than the controls. No toxicity of Seleno-Kappacarrageenan was noted. The above results suggest that the Se can be used as an agent for reducing the nephrotoxicity and bone marrow suppression induced by cisplatin. SN - 0163-4984 UR - https://www.unboundmedicine.com/medline/citation/9197929/full_citation L2 - https://dx.doi.org/10.1007/BF02785304 DB - PRIME DP - Unbound Medicine ER -